Advertisement

Topics

Treanda/Bendeka Market Overview 2019: An Intravenous Cytotoxic Agent – ResearchAndMarkets.com

08:04 EDT 12 Jul 2019 | Biotech 365

DUBLIN–(BUSINESS WIRE)–The “Treanda/Bendeka” report has been added to ResearchAndMarkets.com’s offering. Treanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent. The exact mechanism of action of the drug is still not fully known, but it is a mechlorethamine derivative which has the … Continue reading

Original Article: Treanda/Bendeka Market Overview 2019: An Intravenous Cytotoxic Agent – ResearchAndMarkets.com

NEXT ARTICLE

More From BioPortfolio on "Treanda/Bendeka Market Overview 2019: An Intravenous Cytotoxic Agent – ResearchAndMarkets.com"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...